Skip to search formSkip to main contentSkip to account menu

tivantinib

Known as: c-Met Inhibitor ARQ 197 
An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein… 
National Institutes of Health

Related topics

Related topics

4 relations
ARQ 197MET protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Nivolumab for advanced squamous cell lung cancer: what are the next steps?
Review
2015
Review
2015
Tivantinib for hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) is an aggressive primary tumor of the liver. It mostly occurs in patients with… 
Review
2014
Review
2014
Tivantinib: critical review with a focus on hepatocellular carcinoma
Introduction: Sorafenib is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is an… 
2014
2014
Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
Malignant pleural mesothelioma (MPM) is a lethal disease with scarce therapeutic options, and preclinical studies on new targeted… 
Review
2014
Review
2014
Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.
Introduction Alveolar soft part sarcoma (ASPS) is a rare malignancy that tends to strike young adults and adolescents. It has an… 
Review
2013
Review
2013
Tivantinib in hepatocellular carcinoma
Introduction: Tivantinib (ARQ 197) is a selective, oral MET receptor tyrosine kinase inhibitor with broad-spectrum antitumor… 
2013
2013
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
BACKGROUND Tivantinib (formerly ARQ 197) is a selective inhibitor of c-Met mainly metabolized by CYP2C19. CYP2C19 is known for… 
2013
2013
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter
We read with interest the article by Basilico and colleagues ([1][1]), testing the in vitro activity of tivantinib. The article… 
2013
2013
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
Background:A previous clinical study in non-small cell lung cancer (NSCLC) patients in Western countries suggested the potential… 
2012
2012
Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).
4006 Background: Tivantinib (T) is a selective, oral inhibitor of c-Met, the tyrosine kinase receptor for hepatocyte growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)